Nephros Inc (NEPH) - Total Assets
Based on the latest financial reports, Nephros Inc (NEPH) holds total assets worth $13.64 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Nephros Inc (NEPH) shareholders funds for net asset value and shareholders' equity analysis.
Nephros Inc - Total Assets Trend (2001–2025)
This chart illustrates how Nephros Inc's total assets have evolved over time, based on quarterly financial data.
Nephros Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Nephros Inc's total assets of $13.64 Million consist of 82.3% current assets and 17.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 39.6% |
| Accounts Receivable | $2.41 Million | 17.7% |
| Inventory | $3.23 Million | 23.7% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $318.00K | 2.3% |
| Goodwill | $759.00K | 5.6% |
Asset Composition Trend (2001–2025)
This chart illustrates how Nephros Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Nephros Inc (NEPH) market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nephros Inc's current assets represent 82.3% of total assets in 2025, an increase from 0.0% in 2001.
- Cash Position: Cash and equivalents constituted 39.6% of total assets in 2025, down from 70.1% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is inventory at 23.7% of total assets.
Nephros Inc Competitors by Total Assets
Key competitors of Nephros Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
iRay Technology Co Ltd
SHG:688301
|
China | CN¥11.33 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$272.48 Million |
|
Jiangsu Nanfang Medical
SHG:603880
|
China | CN¥993.46 Million |
|
MEDIMI AB AK
F:79T
|
Germany | €1.70 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.32 Billion |
|
SDI Ltd
AU:SDI
|
Australia | AU$141.20 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
|
Trajan Group Holdings Ltd
AU:TRJ
|
Australia | AU$192.32 Million |
Nephros Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.06 | 5.31 | 10.42 |
| Quick Ratio | 2.89 | 3.64 | 7.09 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.46 Million | $6.74 Million | $13.26 Million |
Nephros Inc - Advanced Valuation Insights
This section examines the relationship between Nephros Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.17 |
| Latest Market Cap to Assets Ratio | 2.42 |
| Asset Growth Rate (YoY) | 21.7% |
| Total Assets | $13.64 Million |
| Market Capitalization | $33.05 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Nephros Inc's assets at a significant premium (2.42x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Nephros Inc's assets grew by 21.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Nephros Inc (2001–2025)
The table below shows the annual total assets of Nephros Inc from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $13.64 Million | +21.69% |
| 2024-12-31 | $11.21 Million | -5.49% |
| 2023-12-31 | $11.86 Million | +7.84% |
| 2022-12-31 | $11.00 Million | -37.68% |
| 2021-12-31 | $17.65 Million | -4.65% |
| 2020-12-31 | $18.51 Million | +59.17% |
| 2019-12-31 | $11.63 Million | +10.14% |
| 2018-12-31 | $10.56 Million | +111.88% |
| 2017-12-31 | $4.98 Million | +86.07% |
| 2016-12-31 | $2.68 Million | -32.54% |
| 2015-12-31 | $3.97 Million | +17.84% |
| 2014-12-31 | $3.37 Million | +16.61% |
| 2013-12-31 | $2.89 Million | -18.11% |
| 2012-12-31 | $3.53 Million | -11.67% |
| 2011-12-31 | $3.99 Million | +151.19% |
| 2010-12-31 | $1.59 Million | -40.05% |
| 2009-12-31 | $2.65 Million | -34.29% |
| 2008-12-31 | $4.04 Million | -59.98% |
| 2007-12-31 | $10.09 Million | +95.19% |
| 2006-12-31 | $5.17 Million | -33.97% |
| 2005-12-31 | $7.82 Million | -35.90% |
| 2004-12-31 | $12.21 Million | +142.50% |
| 2003-12-31 | $5.03 Million | +293.40% |
| 2002-12-31 | $1.28 Million | +223.95% |
| 2001-12-31 | $395.00K | -- |
About Nephros Inc
Nephros, Inc., a commercial-stage company, develops and sells water solutions to the medical and commercial markets in the United States. The company offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and p… Read more